Medium-to-Long Acting Oral Anti-diabetic Drug is classified as a second generation sulfonylurea, which means that it undergoes enterohepatic circulation. Medium-to-Long Acting Oral Anti-diabetic Drug is manufactured by Sri Pharmacare which is WHO-GMP certified. Sri Pharmacare also manufactures various types of pharmaceutical formulations in the form of tablets, capsules, soft gelatine capsules, injections, eye drops, syrups and liquids etc. The Medium-to-Long Acting Oral Anti-diabetic Drug has 5 mg glipizide. This Anti-diabetic Drug blocks the potassium channels in the beta cells of the islets of langerhans. By partially blocking the potassium channels, it increases the time the cell spends in the calcium release stage of cell signalling leading to an increase in calcium which in turn initiates more insulin release from each beta cell.
